Invention Grant
US07879319B2 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
有权
异二聚体融合蛋白可用于靶向免疫治疗和一般免疫刺激
- Patent Title: Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
- Patent Title (中): 异二聚体融合蛋白可用于靶向免疫治疗和一般免疫刺激
-
Application No.: US12498491Application Date: 2009-07-07
-
Publication No.: US07879319B2Publication Date: 2011-02-01
- Inventor: Stephen D. Gillies , Kin-Ming Lo , Yan Lan
- Applicant: Stephen D. Gillies , Kin-Ming Lo , Yan Lan
- Applicant Address: DE Darmstadt
- Assignee: Merk Patent GmbH
- Current Assignee: Merk Patent GmbH
- Current Assignee Address: DE Darmstadt
- Agency: Goodwin Procter LLP
- Main IPC: A61K38/19
- IPC: A61K38/19 ; A61K38/20

Abstract:
Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is used. This consists of first expressing the non-fused p40 IL-12 subunit in a production cell line, followed by or simultaneously expressing in the same cell, a second recombinant fusion protein consisting of the fused polypeptide linked by a peptide bond to the p35 subunit of IL-12. Molecules containing the p35 fusion protein cannot be secreted from the transfected mammalian cell without first complexing in a one to one ratio with the p40 subunit, thus ensuring the production of active heterodimeric fusion proteins.
Public/Granted literature
- US20100015089A1 HETERODIMERIC FUSION PROTEINS USEFUL FOR TARGETED IMMUNE THERAPY AND GENERAL IMMUNE STIMULATION Public/Granted day:2010-01-21
Information query
IPC分类: